# Iovance

Lifileucel（Amtagvi）——首个获批 TIL 药物；费城 iCTC 大型工厂服务数千患者。

Source: https://cn.bioecon.ru/companies/iovance/
Updated: 2026-06-24

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 截至2026年3月31日现金及现金等价物$319 million | https://ir.iovance.com/node/15101/pdf, https://ir.iovance.com/node/15781/pdf |
| 产能 | 目前建成产能可为每年2,000多名患者提供TIL产品，正在扩建以满足每年5,000多名患者的需求 | https://ir.iovance.com/node/14166/pdf, https://ir.iovance.com/node/15101/pdf, https://quarterlytics.com/company/iovance-biotherapeutics_iova/annual-report-2024/, https://www.iovance.com/iovance-cell-therapy-center/, https://www.marketscreener.com/news/iovance-biotherapeutics-corporate-presentation-ce7e5cdadb88f42d, https://www.pharmaceutical-technology.com/projects/iovance-biotherapeutics-cell-therapy-production/, https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm |
| 认证 | 获LEED认证(iCTC) | https://www.iovance.com/iovance-cell-therapy-center/, https://www.pharmaceutical-technology.com/projects/iovance-biotherapeutics-cell-therapy-production/ |
| 监管批准 | 美国FDA于2024年2月16日加速批准Amtagvi（lifileucel）用于治疗晚期黑色素瘤 | https://ir.iovance.com/node/14166/pdf, https://ir.iovance.com/node/15101/pdf, https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/tm247491d1_ex99-1.htm |
| 生产基地 | 位于宾夕法尼亚州费城的Iovance Cell Therapy Center（iCTC） | https://www.iovance.com/iovance-cell-therapy-center/, https://www.pharmaceutical-technology.com/projects/iovance-biotherapeutics-cell-therapy-production/ |
| 营收 | 2026年第一季度产品总收入约为7,100万美元 | https://ir.iovance.com/node/15101/pdf, https://ir.iovance.com/node/15781/pdf, https://last10k.com/sec-filings/iova, https://www.stocktitan.net/sec-filings/IOVA/page-5.html |
| 营收 | 2025 全年总收入为 $2.635亿 | https://last10k.com/sec-filings/iova, https://www.stocktitan.net/sec-filings/IOVA/page-5.html |

独立来源: last10k.com, marketscreener.com, pharmaceutical-technology.com, quarterlytics.com, sec.gov, stocktitan.net

## 技术

- [TIL 疗法（肿瘤浸润淋巴细胞）](https://cn.bioecon.ru/technology/til-therapy/)